Advertisements

Micardis Duo

Quick links to important sections

Micardis Duo

Advertisements
Advertisements

Method of action: Antihypertensive

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Micardis Duo

Quick Facts

Property Description
Active Ingredients Telmisartan and Amlodipine
Form Oral Tablet
Pharmacological Class Antihypertensive Agents (ARB and DHP-CCB)
Common Use Management of High Blood Pressure (Hypertension)
Origin Synthetic Small-Molecule Drugs

Defining Micardis Duo: A Combination Antihypertensive Agent

Micardis Duo is a prescription-only fixed-dose combination medication classified as a synthetic antihypertensive agent used for the continuous management of elevated blood pressure (hypertension). It is manufactured by Boehringer Ingelheim and formulated as a single oral tablet containing two distinct active substances: the Angiotensin II Receptor Blocker (ARB), Telmisartan, and the Dihydropyridine Calcium Channel Blocker (DHP-CCB), Amlodipine. This structure provides the therapeutic efficiency of two established classes of blood pressure medicine in one preparation.

This drug is often used when monotherapy—treatment with a single agent—has proven insufficient to reach target blood pressure levels. The fixed combination is clinically recognized for providing a substantial and sustained blood pressure-lowering effect, which is necessary for effective long-term cardiovascular management.

What Pharmacological Classes are Combined in Micardis Duo?

The medication strategically combines the actions of an Angiotensin II Receptor Blocker and a Calcium Channel Blocker, resulting in a powerful dual blockade of the body’s systems that regulate vascular tension. Telmisartan acts by selectively inhibiting the effects of the vasoconstricting hormone Angiotensin II, while Amlodipine works directly on the smooth muscle walls of the arteries to promote relaxation and vasodilation. Research has confirmed the therapeutic benefit of combining these two antihypertensive classes.

The General Purpose of This Dual Blockade Therapy

The general purpose of Micardis Duo is the effective, long-term management of essential hypertension in adults. It is typically intended for patients whose blood pressure remains insufficiently controlled by the use of either Telmisartan or Amlodipine alone. By delivering this dual blockade within a single-pill combination, the medication simplifies complex regimens and aims to achieve more consistent blood pressure reduction, thereby mitigating the ongoing cardiovascular strain.

Advertisements

What side effects are possible with Micardis Duo?

Possible Side Effects and Safety Information

The safety profile for Micardis Duo (Telmisartan/Amlodipine) is defined by officially documented adverse reactions classified by frequency and body system, as established in regulatory documents like the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC). The most frequent adverse event is peripheral oedema (swelling of ankles/feet), classified as Common (may affect up to 1 in 10 people), which is associated with the Amlodipine component. Other common adverse reactions include dizziness and headache.


System-Organ Classes and Serious Reactions

Adverse reactions are formally grouped into System-Organ Classes (SOCs), including Vascular Disorders (e.g., hypotension, flushing), Nervous System Disorders (e.g., syncope, somnolence), and Gastrointestinal Disorders (e.g., nausea, abdominal pain).

The labeling highlights serious adverse reactions that require specific attention, such as Angioedema (rapid swelling of the face, lips, or tongue), the potential for severe hypotension, and risks related to kidney function, including acute renal failure and hyperkalaemia, which are associated with the Telmisartan component.


Safety Restrictions and Special Populations

Official documents impose strict safety restrictions known as contraindications.

Safety Constraint Condition Officially Listed
Pregnancy Contraindicated during the second and third trimesters due to the risk of fetal injury.
Hepatic Impairment Contraindicated in patients with severe hepatic impairment or biliary obstructive disorders.
Drug-Specific Use Contraindicated with Aliskiren in patients with diabetes or moderate-to-severe renal impairment.

Time-related safety patterns note that hypotension may occur upon treatment initiation in specific patients, and consumption of grapefruit products is not recommended due to potential effects on Amlodipine exposure.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with the Telmisartan and Amlodipine combination is expected to result from the exaggerated pharmacological effects of the active ingredients, as described in regulatory documents. The primary, officially documented manifestation is hypotension (abnormally low blood pressure). Other cardiovascular signs include excessive peripheral vasodilatation and changes in heart rate, such as tachycardia or less commonly, bradycardia.


Severe Outcomes and Emergency Actions

Overdose may lead to marked and probably prolonged systemic hypotension. Severe overdose carries the risk of progression up to and including shock with fatal outcome.

Regulators state that emergency medical attention must be sought immediately upon suspicion of overdose or if symptomatic hypotension occurs. Patients or caregivers are instructed to contact a regional Poison Control Centre without delay.


Supportive Measures

There is no specific antidote known for a Micardis Duo overdose. Management is centered on supportive treatment instituted under medical supervision. Due to the Amlodipine component, measures may include Intravenous calcium gluconate to address calcium channel blockade effects.

Procedural steps described in regulatory guidance that may be utilized to reduce absorption include gastric lavage and the administration of activated charcoal within the first two hours. It is not known whether the Telmisartan component can be removed by hemodialysis.

Advertisements

Therapeutic Uses of Micardis Duo

What Micardis Duo Treats: Main Uses and Benefits

Micardis Duo is commonly used to help manage the chronic condition of Essential Hypertension in adults, especially in situations where sustained blood pressure remains elevated despite prior treatment with a single-agent medication. It is applied when additional supportive symptom management is clearly needed to reduce the overall physiological strain. The overall therapeutic benefit contributes to easing the physiological strain associated with high blood pressure, which supports the key goals of effective hypertension management.

This combination therapy is also considered relevant in clinical settings for high-risk patients, such as those with Type 2 Diabetes Mellitus or a history of manifest cardiovascular disease, where supportive blood pressure management is needed. By helping to reduce chronic pressure overload, the therapy supports the patient's long-term well-being and is relevant for easing the impact of hypertension, which is associated with serious cardiovascular complications. The core therapeutic use involves managing Essential Hypertension and is applied in situations where additional assistance is needed to address elevated blood pressure.

“The primary goal is supporting functional well-being by contributing to the reduction of physiological stress on the circulatory system.”

A key patient-oriented benefit is the convenience of the single-pill combination, which may assist with maintaining functional stability and supports general well-being by simplifying the necessary dual-class therapy. This is applied in situations to help support consistent blood pressure management over the long term.


Quick Fact: Relief for Sustained Pressure Overload
Therapeutic Context Used when Essential Hypertension requires dual-class management.
Target Symptom Elevated Systemic Pressure requiring supportive management.
Patient Benefit Supports the patient during chronic management by easing the impact of pressure overload.

Regulatory References

  1. DailyMed/NIH overview
Advertisements

Eligibility and Restrictions for Use

Micardis Duo, a combination of telmisartan and amlodipine, is prescribed for the treatment of essential hypertension (high blood pressure) in adults. It is typically used as an add-on or replacement therapy for patients whose blood pressure is not adequately controlled with either component drug alone, or for those already taking both components in separate tablets.


Contraindications (Who Should NOT Use It)

This medication is contraindicated and should not be used in the following patient groups:

  • Pregnancy and Breastfeeding: It can harm the unborn baby, especially during the second and third trimesters, and is not recommended during breastfeeding.
  • Hypersensitivity: Patients with a known allergy to telmisartan, amlodipine, or other dihydropyridine derivatives.
  • Severe Hepatic Impairment: Patients with severe liver problems or biliary obstructive disorders.
  • Combination with Aliskiren: Patients with diabetes or moderate to severe kidney impairment who are also taking aliskiren-containing medicines.

Use with Caution (Special Considerations)

Micardis Duo requires careful medical assessment and monitoring in patients with pre-existing conditions, including:

  • Heart problems, such as severe obstructive coronary artery disease or heart failure.
  • Kidney problems, including those on dialysis.
  • Liver impairment (mild to moderate).
  • Volume- or salt-depletion (e.g., from severe diarrhea or vomiting).
  • High levels of potassium in the blood (Hyperkalemia).
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Micardis Duo is complex, documenting interactions based on the distinct pharmacological properties of its two active components, Telmisartan and Amlodipine. Interactions involve both pharmacokinetic (PK) and pharmacodynamic (PD) mechanisms.

Official Restrictions and Monitoring Requirements

Classification Restriction or Requirement
Contraindicated Combination The co-administration of Aliskiren is contraindicated in patients with Diabetes Mellitus due to the Telmisartan component, reflecting the heightened risk of hyperkalemia and decreased renal function.
Dosage Limitation Required The maximum daily dose of co-administered Simvastatin must be strictly limited to 20 mg. This restriction addresses the pharmacokinetic interaction where Amlodipine, acting as a weak CYP3A4 inhibitor, significantly increases Simvastatin exposure.

Documented Exposure and PD Statements

  • Additive Pharmacodynamic Risk: Co-administration with Potassium-sparing Diuretics or Potassium Supplements increases the risk of hyperkalemia. The addition of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may both attenuate the desired blood pressure lowering effect and increase the risk of renal function deterioration.
  • Exposure Monitoring: The Telmisartan component increases the plasma concentration of Digoxin (a P-gp substrate), mandating the monitoring of Digoxin levels. Amlodipine may also increase the blood levels of Tacrolimus and Cyclosporine.
  • Condition-Specific Avoidance: Co-administration of Telmisartan and Aliskiren must be avoided in populations with moderate-to-severe Renal Impairment (GFR less than 60 mL/min).

This structured interaction profile formally defines prohibitions, restrictions, and necessary monitoring procedures as established in government regulatory documentation.

Advertisements

Mechanism of Action

Blocking the Angiotensin II Receptor and Modulating Vascular Tone

The ingredient telmisartan selectively acts as a competitive antagonist of the Angiotensin II Type 1 ( AT1) receptor . By binding to the AT1 receptor, telmisartan prevents Angiotensin II from initiating its signaling cascade within the Renin-Angiotensin-Aldosterone System (RAAS). This action primarily occurs in vascular smooth muscle, leading to vasodilation and a reduction in Systemic Vascular Resistance (SVR), resulting in the modulation of arterial pressure.


Altering Renal Electrolyte Transport and Fluid Balance

The second ingredient, hydrochlorothiazide (HCTZ), functions as an inhibitor of the sodium-chloride cotransporter (NCC) in the kidney's distal convoluted tubules . Inhibition of the NCC prevents the reabsorption of sodium and chloride ions. This mechanism promotes increased excretion of water and electrolytes, causing a decrease in extracellular fluid and plasma volume.


Synergistic Mechanisms of Dual Circulatory Modulation

Micardis Duo's mechanism is characterized by the synergy between these two distinct actions. Telmisartan addresses the resistance component (vessel tone), while HCTZ addresses the volume component (fluid load). By simultaneously modulating SVR and Plasma Volume, the combination exerts a dual-mechanism effect on circulatory hemodynamics.

Advertisements

Dosage and Administration Information

How to Use Micardis Duo

Micardis Duo is a fixed-dose combination medicine approved for oral administration and is taken as one tablet once daily. It is intended exclusively for long-term maintenance in adult patients. This medication is officially designated for individuals whose blood pressure is not adequately controlled by monotherapy with either Telmisartan or Amlodipine alone, or as a replacement regimen for those already stabilized on the two agents taken separately.

To ensure consistent exposure, the tablet should be taken at approximately the same time each day and may be administered with or without food. The tablet must be swallowed whole with water and should not be crushed or chewed.


Official Dosage and Administration Rules

The combination is available in several fixed strengths, with the 80 mg Telmisartan / 10 mg Amlodipine tablet representing the maximum approved daily dosage for the combination.

Dosing Constraint Official Guideline
Dosing Frequency One tablet, once daily.
Maximum Daily Dose 80 mg Telmisartan / 10 mg Amlodipine.
Missed Dose Rule If a dose is missed, it should be skipped if it is almost time for the next scheduled dose; a double dose must not be taken.

Use in Specific Populations

Official regulatory guidelines include specific dosing rules for certain patient groups. For adults with mild to moderate hepatic impairment, the Telmisartan component should not exceed 40 mg daily. Conversely, generally no initial dose adjustment is necessary for older adults or in patients with mild to moderate renal impairment. Use of the product is restricted to adults, as it is not recommended for pediatric patients.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Micardis Duo

Evidence for Use in Essential Hypertension

The clinical evaluation of Micardis Duo is primarily based on short-term randomized controlled trials (RCTs). These studies were structured to explore patterns of response to different study regimens under strict, controlled conditions. Researchers studied adult patients diagnosed with Essential Hypertension, including those with moderate-to-severe forms of the condition.

The central aim of these trials was to measure changes from baseline in seated blood pressure levels. Researchers monitored measurements related to changes in seated trough Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP). Studies described patterns of blood pressure change and examined whether those patterns were different when the dual-component regimen was used compared to using Telmisartan or Amlodipine alone.

Research Evidence in High-Risk Patient Groups

Micardis Duo has been studied in high-risk patient subgroups, such as those with Essential Hypertension who also have Type 2 Diabetes Mellitus. The evidence in this area is largely derived from subgroup analyses of the main RCTs. Researchers examined whether the general patterns of blood pressure measurements observed in the overall hypertensive population were also seen in the subgroup of patients with coexisting diabetes. Research also indicates that the use of Telmisartan alone has been studied in high-risk individuals for measurements during long-term follow-up.

Long-Term Study Design and Durability of Response

The main comparative clinical trials establishing the acute pattern of blood pressure change have had limited follow-up durations, typically lasting between 8 to 12 weeks. While these short-term studies provide insight into the initial response to the combination, they do not characterize long-term patterns of blood pressure control.

Evidence for long-term functional stability and outcomes is largely based on separate, longer-duration studies involving the individual components, Telmisartan and Amlodipine. The durability of the combination's blood pressure-lowering pattern beyond the short-term trial duration remains uncertain based on direct combination research. The certainty regarding long-term outcomes specifically attributable to the combination is limited.

Key Studies & References

  1. Clinical utility of fixed-combination telmisartan–amlodipine in the treatment of hypertension
  2. Effectiveness and safety of telmisartan and telmisartan/amlodipine single-pill combination in the treatment of essential hypertension (TELMISTAR II study)
  3. Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Micardis Duo (FAQ)


Q: What is the main difference between Micardis Duo and taking the two components separately?

According to official prescribing information, Micardis Duo is a fixed-dose combination pill. Its purpose, as a fixed-dose combination, is to provide the required maintenance therapy regimen by replacing the separate intake of Telmisartan and Amlodipine with a single tablet once daily.


Q: Does Micardis Duo contain a diuretic, or is it just the two blood pressure medicines?

Micardis Duo contains the two blood pressure medicines, Telmisartan (an Angiotensin II Receptor Blocker) and Amlodipine (a Calcium Channel Blocker). It does not contain a diuretic component.


Q: Is Micardis Duo known by any other name internationally?

Combination products containing the same active ingredients, Telmisartan and Amlodipine, are marketed under various brand names depending on the country or region of sale. While the names may differ, the core composition of the medicine remains the same.


Q: Can Micardis Duo cause weight changes, according to regulatory documents?

Regulatory safety documents include weight gain as an event reported during post-marketing experience for the components of the drug. However, this is a general listing, and the actual frequency of this event in patients is generally unknown.


Q: Are there any known issues with drinking alcohol while using Micardis Duo?

Official documents indicate that alcohol may have an additive effect in lowering blood pressure when combined with the Telmisartan component. This additive effect may be associated with symptoms like dizziness or fainting.


Q: Do studies suggest Micardis Duo is used for patients who have both high blood pressure and diabetes?

Clinical evaluation of the medicine has included subgroup analyses of patients with essential hypertension who also have Type 2 Diabetes Mellitus. This indicates that researchers specifically examined the patterns of blood pressure change in this patient group.


Q: Can someone who is fasting or intermittent fasting continue to use Micardis Duo?

Official administration instructions state that the tablet may be administered with or without food. The main requirement is that it is taken orally at approximately the same time each day.


Q: What are some of the most frequently reported side effects listed in official sources?

According to regulatory information, the most frequently reported adverse events in clinical trials, listed as Common (up to 1 in 10 patients), were peripheral oedema (swelling of the ankles or feet), dizziness, and headache.


Q: Is a metallic or strange taste a common side effect of Micardis Duo?

A change in taste, known medically as dysgeusia, has been reported in regulatory adverse event listings. It is typically classified as an uncommon or rare side effect for the medicine.


Q: Does Micardis Duo have an interaction with common pain relievers like ibuprofen?

Regulatory documents warn that the combination's components may interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes medicines like ibuprofen. This interaction may lessen the blood pressure-lowering effect and could potentially affect kidney function.


Q: Can Micardis Duo cause problems with kidney function, and how is this monitored?

Official safety information indicates that effects on kidney function are a risk, particularly for certain patients. Patients at risk generally require frequent close monitoring of renal function, electrolytes, and blood pressure.


Q: Is Micardis Duo considered a long-acting medicine, and how long do the effects last?

The medicine is taken once daily for continuous management of blood pressure. Pharmacokinetic data show that the active components have long half-lives, which supports a sustained 24-hour effect.


Q: Are there any known food or drink interactions with this drug?

The tablets may be taken with or without food. However, regulatory documents specifically advise against the consumption of grapefruit products due to a potential increase in the body's exposure to the Amlodipine component.


Q: Is it generally safe to use salt substitutes containing potassium while on Micardis Duo?

Official documents state that the use of potassium-containing salt substitutes or potassium supplements are subject to an official warning, as co-administration is associated with an increased risk of high potassium levels in the blood, known as hyperkalemia.


Q: Does regulatory information mention any potential risks for older adults (seniors)?

While regulatory guidelines state that no initial dose adjustment is necessary for older adults, caution and close monitoring are generally recommended for drug-drug interactions, particularly those that may affect renal function.


Q: Can the ingredients in Micardis Duo affect liver function tests?

Regulatory information notes that the Telmisartan component is primarily eliminated through the bile. For patients with mild to moderate liver impairment, caution is required, and a reduced starting dose may be necessary.


Q: What should a patient do if they accidentally take too many tablets (non-dosing advice)?

Official documents regarding overdosage state that seeking immediate medical attention is required if an accidental overdose is suspected.


Q: Is there research evidence supporting the long-term use of Micardis Duo?

Research documents indicate that the primary comparative clinical trials for the combination product have had limited follow-up durations, typically lasting only 8 to 12 weeks. The certainty regarding long-term outcomes specifically attributable to the combination is described as limited in the research documents.


Q: Can Micardis Duo interact with commonly used over-the-counter supplements?

Specific warnings exist for co-administration with supplements. This includes potassium-containing supplements and the herbal supplement St. John's Wort, as they may affect blood pressure control and/or drug exposure.


Q: Is a mild cough a commonly reported side effect of the components in this medicine?

Coughing has been reported in regulatory adverse event listings for the medicine. It is typically classified as an uncommon side effect, meaning it is not one of the most frequent reactions seen in trials.


Q: How is Micardis Duo different from other Telmisartan combination products?

The difference lies in the second ingredient. Micardis Duo combines Telmisartan with Amlodipine (a calcium channel blocker). Other products, such as MicardisPlus, combine Telmisartan with Hydrochlorothiazide (a diuretic).


Q: Does Micardis Duo contain any ingredients that might be a concern for lactose intolerance?

Regulatory documents indicate that the tablets contain an excipient called lactose monohydrate. This is a concern for patients with rare hereditary problems of galactose intolerance, Lapp Lactase deficiency, or glucose-galactose malabsorption.


Q: Does taking Micardis Duo cause any change in blood sugar levels?

Adverse event listings for the components include reports of changes to blood sugar levels, such as hypoglycaemia (low blood sugar) and hyperglycaemia (high blood sugar). The frequency of these events varies.


Q: Why is Micardis Duo sometimes given in the morning and sometimes at night?

Official use conditions state the tablet should be taken once daily at approximately the same time each day. A specific preference for morning or night is generally not mandated in the prescribing information.


Q: Can official documents clarify if this medicine is safe for women who are breastfeeding?

Regulatory documents state that the medicine's use is subject to a regulatory warning stating it is not recommended during breastfeeding. This is because it is unknown if the components are excreted in human milk and the potential effects on the nursing infant are unknown.


Q: Does Micardis Duo affect my heart rate, or only my blood pressure?

The Telmisartan component generally does not affect pulse rate. However, palpitations (a change in heart rate sensation) is listed as a common adverse reaction for the combination medicine in official documents.


Q: Are there specific instructions for storing the Micardis Duo tablets?

The medication must be stored at 25 C (77 F), protected from moisture, and should remain in the original package until use. This protects the product's stability.


Q: Can Micardis Duo interact with medication used to manage cholesterol?

Regulatory documents specify a pharmacokinetic interaction with the cholesterol medicine Simvastatin, requiring a strict maximum daily dose limit when used together. Information on other cholesterol medicines may also be available.

Advertisements

How should Micardis Duo be stored and disposed of?

Micardis Duo (telmisartan and amlodipine) tablets must be stored according to regulatory requirements to protect the product's stability.

Official Storage Conditions

Requirement Detail
Temperature Store at 25 C (77 F), with excursions permitted between 15 C and 30 C (59 F and 86 F).
Protection Must be protected from moisture; keep the medication in the original package and remove tablets shortly before use.
Child Safety Keep the medication out of the sight and reach of children.

Disposal Instructions

Official disposal rules require that unused or expired Micardis Duo must not be thrown away via wastewater or household waste. Disposal should be handled as pharmaceutical waste by following local requirements or by consulting a pharmacist for guidance on take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Micardis Duo found in:

A-Z Index: